Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

Is there a safe time to discontinue therapy in MS?

Nature Reviews Neurology volume 13, pages 10–11 (2017)Cite this article

Subjects

As yet, no clear strategy has been developed for discontinuation of disease-modifying therapy in multiple sclerosis. A recent observational study adds new information, but the most informative patient groups are still to be assessed comprehensively, and several questions need to be addressed in prospective studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Freedman, M. S. et al. Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Mult. Scler. Relat. Disord. 3, 147–155 (2014).

    Article  Google Scholar 

  2. Bsteh, G. et al. Discontinuation of disease-modifying therapies in multiple sclerosis — clinical outcome and prognostic factors. Mult. Scler. http://dx.doi.org/10.1177/1352458516675751 (2016).

  3. Tobin, W. O. & Weinshenker, B. G. Stopping immunomodulatory medications in MS: frequency, reasons and consequences. Mult. Scler. Relat. Disord. 4, 437–443 (2015).

    Article  CAS  Google Scholar 

  4. Kister, I. et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J. Neurol. Neurosurg. Psychiatry 87, 1133–1137 (2016).

    Article  Google Scholar 

  5. Vellinga, M. M., Castelijns, J. A., Barkhof, F., Uitdehaag, B. M. & Polman, C. H. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70, 1150–1151 (2008).

    Article  CAS  Google Scholar 

  6. Hatcher, S. E., Waubant, E., Nourbakhsh, B., Cravtree-Hartman, E. & Graves, J. S. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 73, 790–794 (2016).

    Article  Google Scholar 

  7. Kappos, L. & European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352, 1491–1497 (1998).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mark S. Freedman is at the Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada.,

    Mark S. Freedman

Authors
  1. Mark S. Freedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark S. Freedman.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Freedman, M. Is there a safe time to discontinue therapy in MS?. Nat Rev Neurol 13, 10–11 (2017). https://doi.org/10.1038/nrneurol.2016.192

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2016.192

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing